CONFERENCE DAY ONE
MAY 19, 2025
PART ONE: FIND YOUR FUTURE PARTNER
Bringing you a targeted and scientifically aligned partnership opportunity from the start, this opening section brings key buyers
together in a unique and unmissable format to find your next partner and route to more capital.
8:45-9:15: Deal-Making for Discovery: activity and ambition for partnerships that will support translational efficacy from
the Pharma Icebreaker
9.15-10.45: Face-to-face matchmaking for protected networking time during the Pharma Matchmaking Roundtables, to
qualify, hear feedback, and generate interest for the rest of the conference
11.45-12.15: Business panel to hear differences in experience and advice from representatives of deals from the
last 12 months
7:30 am
One-on-One Partnering portal meeting schedule starts. Grab a coffee and sit down with key contacts in the hour before the conference at bookable meeting spaces.
8:40 am Chair’s Opening Remarks
Strategic Priorities & Deal Trends: Which Problems are we Solving with Innovative Technologies & How are Collaborations Advancing Clinical Translation of Induced Proximity
Strategic Priorities & Deal Trends: Which Problems are we Solving with Innovative Technologies & How are Collaborations Advancing Clinical Translation of Induced Proximity
8:45 am Pharma Icebreaker: Activity & Ambition for Deal Making to Expand the Drug Discovery Toolbox
Synopsis
• Understanding and appreciating why pharma would invest: What gap are the innovative technologies filling and what problem are they solving?
• How do research collaborations support translational efficiency of protein degradation clinical development? Where do we need to improve to clinically validate more protein degradation programs?
• Which technologies and targets invite interest – how does this play through into disease areas of interest?
9:15 am Pharma Icebreaker Roundtables:Ensure you Connect
Synopsis
For interested parties to guarantee meeting time with each other, both pharma and attending biotech can select companies of interest for a pre-organized rotations across 90 minutes. Meet face-to-face with priority companies, and benefit from introducing yourself to pharma you have not scheduled meetings with through the One-on-One Partnering portal early in the event.
10:45 am
Morning Break & Networking
11:00 am
One-to-One Meeting Opportunity
11:45 am Business Panel: Effectively & Efficiently Structuring Deal Processes as an Early-Stage Company in TPD
Synopsis
• Discussing the panel’s experience executing deals, including how to manage alliances to grow more deals
• Outlining opportunities and experience for creative deal structures, and when and where they would be appropriate
12:15 pm
Lunch Break & Networking
12:30 pm
One-to-One Partnering Meeting Opportunity
PART TWO: SCIENTIFIC SHOWCASE
Designed to foster excitement and engagement in innovative companies, be part of back-to-back presentations to validate your
technology as solving scientific hurdles and differentiated versus peers to a group of aligned and qualified decision-makers.
Scientific Session Chair: Ann Rowley - Director Targeted Protein Degradation - Merck
Expanding the E3 Ligase Target Universe
Expanding the E3 Ligase Target Universe
1:40 pm Targeting Chromatin Modulators with Therapeutic Degraders
Synopsis
• Applying degradation to achieve selectivity
• Exploration of varying E3 ligase activity
• Expanding degrader delivery and formulation
2:00 pm Discovery of Novel E3 Ligands for Targeted Protein Degradation
Synopsis
• Discussing how cullin-RING E3 ligases (CRLs) are better suited for developing novel E3 ligands due to their multi-subunit assembly mechanism and intrinsic structural flexibility
• What factors to consider for the selection of E3 ligases for developing E3 ligands?
• Updating on discovery of novel E3 ligands at Cullgen
2:20 pm Discovery of Molecular Glue Degrader of KRAS Mutants for Treatment of Lung, Colon & Pancreatic Cancer
Synopsis
- Sharing the discovery of a new molecular glue degrader of KRAS mutants
- Discussing the MOA and the engagement of a new E3 ligase
- Providing initial proof of concept and overview of the KRAS programÂ
2:40 pm
Afternoon Break & Networking
3:00 pm
One-to-One Partnering Networking
4:10 pm Development of Oral ATAC Degraders for Extracellular Proteins
Synopsis
- Harnessing natural cellular degradation machinery to eliminate pathogenic extracellular proteins ATACs (ASGPR-Targeting Chimeras)
- Discussing Avilar's proprietary ASGPR ligands deliver superior affinity and optimized ADME properties, enabling differentiated product profiles. Also detailing from concept to candidate: Avilar’s systematic approach to developing oral ATACs
- Sharing ASGPR ligand optimization for continued improvement in oral bioavailability
- Achieving high oral bioavailability with multiple prototype ATACs targeting diverse proteins, including for Avilar’s cardiometabolic program
4:30 pm Polymed’s Optimized PROTAC & DAC Programs
Synopsis
- Sharing novel approach to optimizing PROTAC potency and selectivity
- Discussing collaboration with Photys Therapeutics on IRAK4 PROTAC HBP/PHT-776
- Updating on Polymed's PROTAC and DAC pipeline: EGFR and KRAS G12D
4:50 Drinks Reception:
Enjoy an informal networking drinks reception with all attending and presenting companies to catch up with key stakeholders outside of the regular meeting, as a touchpoint ahead of BIO.